Neurodegenerative Diseases

News

Alector ditches GSK-partnered dementia drug and cuts staff

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

R&D

Alzheimer’s research: Cutting through the noise to find the ...

A closer look at how clinical trials for Alzheimer’s have evolved and what this means for patients and sites, with Medidata and Cogstate.

News

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Alchemab's chief executive, Jane Osbourn

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

Alector ditches GSK-partnered dementia drug and cuts staff

Alzheimer’s research: Cutting through the noise to find the ...

Joy as uniQure Huntington's therapy clears pivotal trial

Bayer starts pivotal Parkinson's cell therapy trial

NRG raises £50m to start trials of Parkinson's, ALS drug

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Neurodegenerative Diseases

Editor's Picks